Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

Monday, July 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has reported positive preclinical results for SKNY-1, its oral drug candidate targeting obesity and addiction. The studies show favorable oral bioavailability, significant brain penetration, and liver exposure, suggesting a potential for once-daily dosing. These findings mark a significant advancement in the development of SKNY-1.
Price reaction · baseline $0.9448 (2026-07-02 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close · peak
+1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful formulation results for SKNY-1.
  • Demonstrated favorable oral bioavailability.
  • Robust brain penetration and liver exposure.
  • Potential for once-daily dosing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with Once-Daily Dosing Potential MIAMI, FL / ACCESS Newswire / July 6, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company, today announced positive results from preclinical studies evaluating the optimized oral formulation of SKNY-1, the Company’s oral drug candidate being developed for obesity and addiction-rela…
You can read the full content here

Frequently Asked Questions

What is SKNY-1 developed for?

SKNY-1 is an oral drug candidate developed for obesity and addiction.

What were the results of the preclinical studies?

The preclinical studies showed favorable oral bioavailability and robust brain penetration.

What is the dosing potential for SKNY-1?

SKNY-1 has the potential for once-daily dosing.

Which company is developing SKNY-1?

SKNY-1 is being developed by MIRA Pharmaceuticals, Inc.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals SKNY-1 obesity addiction preclinical results
Last updated: Jul 6, 2026

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →